We are live on ! Find out more
WVP

Worth Venture Partners Portfolio holdings

AUM $31.6M
1-Year Est. Return 28.5%
This Fund
S&P 500
This Quarter Est. Return
+3.95%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$47.3M
Cap. Flow
-$45.9M
Cap. Flow %
-25.57%
Top 10 Hldgs %
70.76%
Holding
129
New
37
Increased
17
Reduced
26
Closed
31

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$4.98M
2
AMGN icon
Amgen
AMGN
+$2.4M
3
BKNG icon
Booking.com
BKNG
+$2.14M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.13M
5
NNDM
Nano Dimension
NNDM
+$1.39M

Top Sells

Rank Stock Value
1
QCOM icon
Qualcomm
QCOM
+$2.81M
2
SPSB icon
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
+$2.32M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$1.44M
4
CALX icon
Calix
CALX
+$1.11M
5
VCSH icon
Vanguard Short-Term Corporate Bond ETF
VCSH
+$1.01M

Sector Composition

Rank Sector Weight
1 Healthcare 8.5%
2 Technology 5.71%
3 Consumer Discretionary 1.17%
4 Industrials 1.07%
5 Energy 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLNX
26
DELISTED
Xilinx Inc
XLNX
$634K 0.35%
5,000
-8,000
-62% -$899K
XLI icon
27
State Street Industrial Select Sector SPDR ETF
XLI
$32.2B
$619K 0.34%
8,254
-353
-4% -$25.6K
LJPC
28
DELISTED
La Jolla Pharmaceutical Company
LJPC
$615K 0.34%
+95,607
New +$623K
VGT icon
29
Vanguard Information Technology ETF
VGT
$133B
$606K 0.34%
24,168
-20,616
-46% -$479K
DERM
30
DELISTED
Dermira, Inc.
DERM
$596K 0.33%
+44,000
New +$367K
DMAC icon
31
DiaMedica Therapeutics
DMAC
$341M
$544K 0.3%
119,863
-10,000
-8% -$36.1K
CORV
32
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$544K 0.3%
+172,066
New +$557K
MX icon
33
Magnachip Semiconductor
MX
$110M
$518K 0.29%
70,050
-41,250
-37% -$293K
RFIL icon
34
RF Industries
RFIL
$116M
$516K 0.29%
+76,572
New +$574K
NNDM
35
Nano Dimension
NNDM
$314M
$486K 0.27%
+146,297
New +$1.39M
LUMO
36
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$475K 0.26%
+27,294
New +$407K
RIGL icon
37
Rigel Pharmaceuticals
RIGL
$723M
$463K 0.26%
21,914
+13,174
+151% +$301K
ADMS
38
DELISTED
Adamas Pharmaceuticals
ADMS
$425K 0.24%
+59,740
New +$537K
ACHV icon
39
Achieve Life Sciences
ACHV
$633M
$399K 0.22%
6,183
+1,701
+38% +$68.7K
APVO icon
40
Aptevo Therapeutics
APVO
$4.96M
– –
0
– –
BNGO icon
41
Bionano Genomics
BNGO
$12.5M
$382K 0.21%
146
+13
+10% +$34.1K
OEF icon
42
PUT
iShares S&P 100 ETF
OEF
$19.5B
$380K 0.21%
+50,000
New +$6.02M
XLF icon
43
State Street Financial Select Sector SPDR ETF
XLF
$56.5B
$374K 0.21%
14,567
-4,202
-22% -$108K
FLNA
44
Filana Therapeutics
FLNA
$42M
$372K 0.21%
288,363
+280,185
+3,426% +$321K
QTNA
45
DELISTED
Quantenna Communications, Inc. Common Stock
QTNA
$368K 0.21%
15,119
-37,490
-71% -$653K
XLP icon
46
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.6B
$364K 0.2%
6,489
-374
-5% -$20K
XPH icon
47
State Street SPDR S&P Pharmaceuticals ETF
XPH
$481M
$359K 0.2%
8,635
+133
+2% +$5.41K
TMDI
48
DELISTED
Titan Medical Inc. Ordinary Shares
TMDI
$321K 0.18%
+114,886
New +$376K
CHK
49
DELISTED
Chesapeake Energy Corporation
CHK
$307K 0.17%
+496
New +$278K
TPST icon
50
Tempest Therapeutics
TPST
$14.3M
$276K 0.15%
94
-39
-29% -$86.3K
1
2
3 4 5

Similar funds

VL
Vorpal LLC Nashville, Tennessee $32M AUM 10.89% 1-Year Est. Return
WTG
West Tower Group Richmond, Virginia $32.1M AUM 33.19% 1-Year Est. Return
QCA
Quantify Chaos Advisors Brooklyn, New York $32.1M AUM
SP
SCF Partners Houston, Texas $32.2M AUM 191.71% 1-Year Est. Return
OGC
One68 Global Capital New York $30.9M AUM
PE
Platinum Equity Beverly Hills, California $32.3M AUM 17.64% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Worth Venture Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Worth Venture Partners held 129 positions worth $180M, up 36% from $132M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Worth Venture Partners withdrew a net $45.9M in Q1 2019, closing 31 positions and reducing 26 holdings. Its most notable exit was State Street SPDR Portfolio Short Term Corporate Bond ETF, an estimated $2.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.5% of assets, up from 3.7% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Worth Venture Partners opened a new position in Biogen worth $3.73M.

  • Worth Venture Partners's largest Q1 2019 buy was Biogen: 15,800 shares worth $3.73M.
  • Worth Venture Partners added most to BioMarin Pharmaceuticals in Q1 2019, an estimated $2.13M increase.
  • Worth Venture Partners's biggest Q1 2019 reduction was Qualcomm, cutting an estimated $2.81M.
  • Worth Venture Partners fully exited State Street SPDR Portfolio Short Term Corporate Bond ETF in Q1 2019, selling an estimated $2.32M.
  • Worth Venture Partners's ten largest holdings make up 71% of its $180M portfolio in Q1 2019.
  • Worth Venture Partners opened 37 new positions and closed 31 in Q1 2019.
  • Worth Venture Partners's portfolio value rose 36% quarter-over-quarter to $180M.

Based on Worth Venture Partners's 13F filing for Q1 2019, filed 15 May 2019.